Ingersoll Rand (IR) investor relations material

Business performance and market trends

• Organic revenue shifted from a 1% decline in Q1 to 4% growth in Q2, with July orders showing further acceleration, especially in long-cycle projects.

• Growth is broad-based across end markets and regions, with Americas showing high single-digit order momentum and India and Latin America highlighted for outsized growth potential.

• Investments in new facilities and commercial capabilities over the past 12–18 months are contributing to improved performance and are expected to yield further benefits in the next year.

• Both short/medium and long-cycle businesses are gaining traction, with long-cycle project momentum expected to continue, supported by trends like nearshoring and semiconductor expansion.

• China has reset to a smaller share of revenue, with volumes recovering but pricing still lagging; normalization is expected over time as market stability returns.

Strategic initiatives and growth drivers

• Engineer-to-order solutions and vertical market approaches are being leveraged to create unique, modular offerings, with global engineering and manufacturing support.

• Aftermarket business, representing about 40% of sales, is growing in absolute terms, with a focus on long-term service agreements and remote monitoring to drive recurring revenue.

• M&A remains disciplined, with a robust pipeline of bolt-on opportunities and no immediate need for transformational deals; focus is on targets with strong gross margins and aftermarket potential.

• Financial flexibility is maintained, with leverage at 1.7x and $4 billion in liquidity, allowing for opportunistic acquisitions if unique opportunities arise.

• AI and data center exposure is still nascent, but ongoing customer engagement and solution development could open new avenues for growth.

Margin outlook and operational execution

• ITS margins are expected to recover as price/cost dynamics improve and restructuring benefits materialize in the second half; long-term margin targets remain at ~30%.

• PST margins are strong, with Q2 at 31.5% and a path to mid-30s driven by integration, growth in life sciences, and continued operational improvements.

• Pricing actions are tailored by region and product, with 1%-2% annual price realization expected through the cycle outside China.

• Execution risks are balanced across pricing, productivity, and volume, but management expresses confidence in achieving sequential margin improvement in the back half.

• Medium-term margin expansion is anticipated as growth normalizes and both ITS and PST approach their respective targets.